George Addona News Today : Breaking News, Live Updates & Top Stories | Vimarsana

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

Initial Focus on One Oncology Target, Exclusive to Collaboration; Merck has Option for Three Additional TargetsWATERTOWN, Mass., Dec. 12, 2023 C4 Therapeutics, Inc. , a clinical-stage.

George addonaCourtney solbergAndrew hirschLoraine spreenMerck research laboratoriesCorporate communications patient advocacyTherapeutics incExchange commissionInitial focusOne oncology targetThree additionalMerck researchPrivate securities litigation reform actAnnual reportQuarterly reportCorporate communications

C4 Therapeutics Inc (CCCC) Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates

C4 Therapeutics Inc (CCCC) Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Andrew hirschGeorge addonaTherapeutics incMerck research laboratoriesMerck research

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop

WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation

Andrew hirschGeorge addonaLoraine spreenCourtney solbergMerck research laboratoriesCorporate communications patient advocacyTherapeutics incExchange commissionMerck researchPrivate securities litigation reform actAnnual reportQuarterly reportCorporate communicationsPatient advocacy

Merck to Acquire Caraway Therapeutics, Inc

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. announced today that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Caraway Therapeutics for a total potential consideration of up to $610 million .

United statesUnited kingdomMartind williamsGeorge addonaMerck research laboratoriesMerck co incCaraway therapeutics incDementia discovery fundStatement of merck co incVentures fundSv health investorsExchange commissionCaraway therapeuticsMerck researchAbbvie venturesAmgen ventures

Merck to acquire Caraway Therapeutics in a deal worth up to $610m

Merck to acquire Caraway Therapeutics in a deal worth up to $610m
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Daiichi sankyoGeorge addonaMartin williamsMerck coMerck research laboratoriesCaraway therapeuticsPrometheus biosciences